Details for Patent: 5,234,906

Title:	Hyperglycemic compositions
Abstract:	Compositions having amylin or an amylin agonist and a glucagon compound, particularly peptide compounds, for the control of glucose production in mammals are provided. The compositions are useful in the treatment of hypoglycemia, including acute hypoglycemic conditions such as those brought on by insulin overdose and the overuse of oral hypoglycemic agents.
Inventor(s):	Young; Andrew (San Diego, CA), Cooper; Garth J. S. (Solana Beach, CA)
Assignee:	Amylin Pharmaceuticals, Inc. (San Diego, CA)
Filing Date:	Jan 10, 1991
Application Number:	07/640,478
Claims:	1. A composition comprising glucagon and an amylin admixed in a form suitable for therapeutic administration. 2. A composition comprising a glucagon compound and an amylin agonist admixed in a form suitable for therapeutic administration. 3. The composition of claim 1 wherein said amylin is rat amylin. 4. The composition of claim 2 wherein said amylin agonist is a calcitonin gene-related peptide. 5. The composition of any of claims 1, 2 or 3 which is in lyophilized dosage unit form. 6. A method for enhancing glucose levels in a mammal, which comprises the administration of a therapeutically effective amount of the composition of any of claims 1, 2, 3 or 4. 7. A method for the treatment of acute hypoglycemia in mammals, which comprises the administration of a therapeutically effective amount of the composition of any of claims 1, 2, 3 or 4. 8. The method of claim 6 wherein said administration is by parenteral injection. 9. The method of claim 7 wherein said administration is by parenteral injection. 10. The method of claim 6 wherein said administration is by intravenous infusion. 11. The method of claim 7 wherein said administration is by intravenous infusion. 12. A method for the control of hypoglycemic conditions in mammals, which comprises the co-administration of therapeutically effective amounts of a glucagon compound and an amylin agonist. 13. The method of claim 12 wherein said amylin agonist is amylin. 14. The method of claim 12 wherein said amylin agonist is a calcitonin gene-related peptide. 15. A method for the treatment of acute hypoglycemia in mammals, which comprises the co-administration of therapeutically effective amounts of a glucagon compound and an amylin agonist. 16. The method of claim 15 wherein said amylin agonist is amylin. 17. The method of claim 15 wherein said amylin agonist is a calcitonin gene-related peptide. 18. The composition of claim 1 wherein said amylin is human amylin. 19. The composition of claim 2 wherein said amylin agonist comprises an amylin having a proline residue at amino acid position 29. 20. The composition of claim 2 wherein said amylin agonist comprises an amylin having a leucine residue at amino acid position 23. 21. The method of claim 12 wherein said amylin agonist comprises an amylin having a proline residue at amino acid position 29. 22. The method of claim 15 wherein said amylin agonist comprises an amylin having a proline residue at amino acid position 29. 23. The method of claim 12 wherein said amylin agonist comprises an amylin having a leucine residue at amino acid position 23. 24. The method of claim 15 wherein said amylin agonist comprises an amylin having a leucine residue at amino acid position 23.